Ophthalmic composition comprising a synergistic combination of Polglumyt® and Sodium Hyaluronate.
Liberati E, Russo V, Santo G, Durando L, Marchitto L, Ragni L, Tongiani S.
Poster session presented at: AAPS; 2017 Nov 12-15; San Diego, CA (USA).
“Ottimizzazione della miscelazione di un principio attivo a basso dosaggio in una formulazione in compresse”
S. Selva, L. Donati, L. Marchitto
Presentation Workshop “Continuous improvement nel farmaceutico: casi positivi di applicazioni Lean Six Sigma e Quality by Design”
11-13 June 2008 Proceedings 48 ° Simposio AFI Rimini, 2008
Evaluation of the Mixing Effectiveness of a New Powder
Mixer
Giovanni Filippo Palmieri, Debora Lovato, Leonardo Marchitto,
Aldo Zanchetta, Sante Martelli
Drug Development and Industrial Pharmacy, 1998, Vol. 24,
No. 1 : Pages 81-88
Abstract: The effectiveness of the new powder
mixer Canguro J tumbler was evaluated using lactose,
microcrystalline cellulose, and salicylic acid as chemical
indicator with the ratio 88:10:2 (w/w). The mixing time, the speed
of the tumbler (rpm), its inclination, and filling percentage were
varied in order to assess the limits of the mixer and the best
parameters to use for obtaining a mixture as uniform as possible.
The same experiments were then repeated after addition of 1% (w/w)
magnesium stearate to the mixture of powders. The efficiency in the
distribution of this lubricant was estimated by the progressive
hardness reduction of the tablets derived from the compression of
the powders, at a constant applied force. Finally, a comparison
between Canguro J and a very efficient V-shaped mixer of the same
capacity was performed. The results show that all investigated
parameters influenced the mixing capability of Canguro J. The best
effectiveness of the mixer occurred at the filling rate of 50% and
a rotation speed of 20 rpm; in this case, Canguro J is even a
little more effective than the V-shaped mixer. However, even at the
filling rate of 70%, the same distribution uniformity of the
powders can be obtained after a mixing time protraction of a few
minutes.
Patents:
1) CONTROLLED
RELEASE PHARMACEUTICAL OR FOOD FORMULATION AND PROCESS FOR ITS
PREPARATION. EU Patent WO2010084038 (A1) ;
US2011318321 (A1)
The present invention relates to a controlled release
pharmaceutical or food formulation comprising at least one active
pharmaceutical or food ingredient dispersed in a mixture of a
glycogen with a polysaccharide, and the process for its
preparation. The invention also relates to a slow release system
represented by a mixture of a glycogen with a polysaccharide, and
its use for the preparation of slow release pharmaceutical or food
formulations.
2) A
SLOW-RELEASE FORMULATION BASED ON AN ASSOCIATION OF GLYCOGEN AND
ALGINATE
US 2010/0255083A1; EU Patent Application WO2009083561
Inventors: Leonardo Marchitto
The invention relates to a controlled-release pharmaceutical
formulation comprising at least one
active ingredient dispersed in a matrix comprising at least one
slow-release excipient comprising an
association of at least one glycogen and at least one alginate
with alkaline-earth metal salts, and a process for its preparation.
The invention also relates to a slow-release excipient comprising
an association of at least one glycogen and at least one alginate
with alkaline-earth metal salts, and the process for its
preparation, and its use for the preparation of slow-release
pharmaceutical formulations.
3)
PHARMACEUTICAL PREPARATION COMPRISING LYOPHILIZED
LIPOSOMES
ENCAPSULATING AN ACTIVE PRINCIPLE WHICH IS HIGHLY
INSOLUBLE IN WATER, AND THE PROCESS FOR PREPARING THE SAID
PREPARATION
EU Patent EP0981332B1
Inventors: Leonardo Marchitto
Lyophilized composition comprising trehalose and lipid liposomes
in which a biologically-active principle has been incorporated,
characterized in that the biologically-active principle is highly
insoluble in water, the trehalose/lipid weight ratio is </= 1.5,
and all of the trehalose was added to the outside of the liposomes
already formed before lyophilization.
4) AQUEOUS
PHARMACEUTICAL COMPOSITION COMPRISING AN ACTIVE INGREDIENT WHICH IS
HIGHLY INSOLUBLE IN WATER
EU Patent EP0973505B1;
Inventors: Leonardo Marchitto
Aqueous pharmaceutical composition comprising an active
ingredient which is highly insoluble in water, dispersed in
liposomes and method of preparation thereof.
5) ORALLY
DISPERSIBLE PHARMACEUTICAL COMPOSITION AND PROCESS FOR THE
PREPARATION THEREOF
EU Patent EP1819320B1
Inventors: Leonardo Marchitto
A process for preparing an orally dispersible solid
pharmaceutical form comprises the following steps: a)coating the
active ingredient with at least one hydrophilic carboxylate
polymer, b) granulating the coated active ingredient obtained in
step (a) with at least one lipid compound having a melting point
lower than thatof the active ingredient, c) mixing the granulate
obtained in step (b) with at least one hydrophilic natural polymer
having high molecular weight, and d) mixing the granulate obtained
in step (c) with ingredients suitable for obtaining an orally
dispersible solid pharmaceutical form. An orally dispersible solid
pharmaceutical form comprises an active ingredient coated with at
least one hydrophilic carboxylate polymer and at least one lipid
compound, in which the said coated active ingredient is embedded in
a matrix comprising at least one hydrophilic natural polymer having
high molecular weight.
6)
PHARMACEUTICAL ORAL DOSAGE FORM COMPRISING A NON-STEROIDAL
ANTI-INFLAMMATORY DRUG, AND HAVING GOOD PALATABILITY
EU Patent EP1694295B1
Inventors: Leonardo Marchitto
Oral pharmaceutical dosage form comprising tromethamine and a
NSAID selected from the group comprising ibuprofen, naproxen and
flurbiprofen, characterized in that it also comprises a compound
selected from the group comprising glycine, vitamine B6 and
mixtures thereof.
7) COSMETIC
COMPOSITION COMPRISING GLYCOGEN FOR SKIN APPLICATION WITH VELVET
EFFECT
eu Patent WO2009095341 (A1) ; EP2240154 (A1)
Inventors: Leonardo Marchitto
This invention relates to a cosmetic composition for skin
application having a velvet effect on the skin comprising, as the
cosmetic active ingredient, a glycogen having less than 1,000 ppm
of nitrogen and less than 1% by weight of reducing sugars, in at
least one cosmetically-acceptable vehicle.
8) Hydrophilic
pharmaceutical composition having anti- inflammatory
activity
eu Patent IT1992MI01749 19920717
Inventors: Leonardo Marchitto
A topical pharmaceutical composition in the form of a foam
having anti-inflammatory activity which contains a suitable soluble
salt of a compound selected from the group comprising
2-(2,6-dichlorophenyl) amino benzyl acetic acid and
4-hydroxy-2-methyl-N-2-pyridinyl-2H-1,2-
benzothiazine-3-carboxamide 1,1-dioxide as active ingredient is
described.
9) OPHTHALMIC
SOLUTION COMPRISING GLYCOGEN
EP 1069885 B1 Inventors: Leonardo Marchitto
An ophthalmic solution comprising a sterile aqueous solution of
a glycogen polysaccharide.
10 ) USE OF AN L-ASCORBIC ACID SALT TO PREPARE A
PHARMACEUTICAL COMPOSITION FOR OPHTHALMIC TOPICAL USE CAPABLE
OF IMPROVING THE LEVEL OF L-ASCORBIC ACID IN THE EYE
EU Patent EP1485084B1
Inventors: Leonardo Marchitto
Use of a salt of L-ascorbic acid with a pharmaceutically
acceptable organic base to prepare a pharmaceutical composition,
for ophthalmic topical use, capable of improving the level of
L-ascorbic acid in a human eye.
